FDA push for cheaper ‘biosimilar’ drugs could challenge pharma’s biggest blockbusters
March 29, 2018 at 12:06 PM EDT
The regulator wants to bolster competition for cancer and rheumatoid arthritis drugs, among others.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.